NICE changes tack on NHS use of BMS' myelofibrosis drug Inre...

After turning down routine NHS funding of Bristol-Myers Squibb's Inrebic for bone marrow disorder myelofibrosis earlier this year, NICE now says the drug can be made available via the Cance